WO2001091777A1 - An-egg protein anti-cancer injection drug and a procedure to obtain such a drug - Google Patents

An-egg protein anti-cancer injection drug and a procedure to obtain such a drug Download PDF

Info

Publication number
WO2001091777A1
WO2001091777A1 PCT/KR2001/000897 KR0100897W WO0191777A1 WO 2001091777 A1 WO2001091777 A1 WO 2001091777A1 KR 0100897 W KR0100897 W KR 0100897W WO 0191777 A1 WO0191777 A1 WO 0191777A1
Authority
WO
WIPO (PCT)
Prior art keywords
injection
drug
regarding
procedure
patient
Prior art date
Application number
PCT/KR2001/000897
Other languages
French (fr)
Inventor
Moo Chul So
Sung Guen So
Moo Sung So
Original Assignee
Moo Chul So
Sung Guen So
Moo Sung So
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moo Chul So, Sung Guen So, Moo Sung So filed Critical Moo Chul So
Priority to AU2001264339A priority Critical patent/AU2001264339A1/en
Publication of WO2001091777A1 publication Critical patent/WO2001091777A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9755—Gymnosperms [Coniferophyta]
    • A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • This invention relates to an inject-able drug that is claimed to be effective in treating various cancers, tuberculosis, inflammatory diseases including nephritis and other kidney problems, various liver problems including hepatitis, arthritis, and dermatitis, and the procedure by which such a drug is obtained.
  • the invention relates to an inject-able drug that is claimed to be effective in treating tuberculosis, various cancers and other inflammatory diseases such as nephritis and other kidney problems, hepatitis and other liver disorders, arthritis, and dermatitis; and to the procedure by which such a drug is obtained.
  • the reactions of egg proteins were modified to create a protein-based treatment that has a physiological activation effect as well as anti-bacterial effect on the human body.
  • the protein enzymes were decomposed to produce the drug.
  • the main ingredients of the drug are the yellow and white parts of an egg, and pine Resin rosin or pine needle oil. These ingredients are then mixed in a treatment kettle in 1:1, 1:2 or 1 :3 proportions based on weight. Then, the solid chemical compound formed by heating at 60 ⁇ 130 ° C and cooling is re-heated using distilled water for precipitation and purification.
  • the filtered herbal medicinal liquid produced in Case Study 1 was filtered using a high- precision filter to yield inject-able liquid.
  • a tuberculosis patient (34 years old, male, inflicted with Tuberculosis for 1 year and
  • Chronic nephritis patient (36 years old, female, oliguria, proteinuria, the whole body edema) was given intramuscular injection for 2 days (once a day, 2ml, dose per injection). The whole body edema disappeared and proteinuria and oliguria disappeared after 5 days of continued intramuscular injection. After 30 days of intramuscular injections (once a day, 2 ⁇ per injection), the patient was cured.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to i) an inject-able drug that is claimed to be effective in treating tuberculosis, various cancers and other inflammatory diseases such as nephritis and other kidney problems, hepatitis and other liver disorders, arthritis, and dermatitis; and to ii) the procedure by which such a drug is obtained. The drug consists of activated protein compounds obtained using a process involving heating, precipitation and purification of a mixture containing the yellow and white parts of an egg, and pine Resin rosin or pine needle oil.

Description

An Egg Protein Anti-Cancer Injection Drug and a Procedure to Obtain Such a Drug
[Background]
This invention relates to an inject-able drug that is claimed to be effective in treating various cancers, tuberculosis, inflammatory diseases including nephritis and other kidney problems, various liver problems including hepatitis, arthritis, and dermatitis, and the procedure by which such a drug is obtained.
In general, various treatment methods for the above-mentioned diseases exist. These methods include surgery, use of antibiotics, chemotherapy, etc. However, these treatments have side effects that usually damage the liver. As the use of existing antibiotics increases, the tolerance level not only increases, but recovery is likewise impeded. The use of chemotherapy causes the liver, stomach and other internal organs to deteriorate. To overcome these negative side effects, the reactions of egg proteins were modified in such a way as to develop a protein-based drug that has a physiological activation effect as well as anti-bacterial effect on the human body. This invention has paved the way for three categories of therapeutics under the production phase: anti- bacteria, chemotherapy and protein-based treatment. [Description]
The invention relates to an inject-able drug that is claimed to be effective in treating tuberculosis, various cancers and other inflammatory diseases such as nephritis and other kidney problems, hepatitis and other liver disorders, arthritis, and dermatitis; and to the procedure by which such a drug is obtained. The reactions of egg proteins were modified to create a protein-based treatment that has a physiological activation effect as well as anti-bacterial effect on the human body. The protein enzymes were decomposed to produce the drug.
The main ingredients of the drug are the yellow and white parts of an egg, and pine Resin rosin or pine needle oil. These ingredients are then mixed in a treatment kettle in 1:1, 1:2 or 1 :3 proportions based on weight. Then, the solid chemical compound formed by heating at 60~ 130°C and cooling is re-heated using distilled water for precipitation and purification.
[Optimal Embodiment of the Invention]
This invention is described in detail using the following case studies:
(Case Study 1) 60g of the yellow and white parts of an egg and 120g of pine resin were mixed and heated at 60 ~ 130°C for approximately 40~45 minutes and then cooled. 7 ml, of distilled water was added for eveiy 1 g of solid chemical compound produced. The reheating process lasted for about 30 min. The compounds were then cooled and the filtered herbal medicinal liquid was poured into a container. (Case Study 2)
The filtered herbal medicinal liquid produced in Case Study 1 , was filtered using a high- precision filter to yield inject-able liquid.
(Experiment 1) Toxic Test 1) Materials for Experimentation: Liquid for injection produced in Case Study 2 and drug for oral administration produced in Case Study 3. 2) Subjects: 10 pigs (sampled randomly, since the weight of the animals were not relevant to the experiment, which only sought to observe the existence or nonexistence of toxicants) 3) Experimental method: Liquid for injection produced in Case Study 2 was injected onto the animals (10 pigs) for 10 days (once a day, 4ml per injection). 4) Results: After 1 month of observation, no significant change in weight, behavior and amount of diet was seen on any of the animals in both groups.
(Experiment 2) As an Anti-Tuberculosis Drug
1) Liquid for injection produced in Case Study 2
A tuberculosis patient (34 years old, male, inflicted with Tuberculosis for 1 year and
6 months) was given intramuscular injection once a day (2iiifidosage per injection).
The patient's appetite increased the next day, and his pattern of coughing up phlegm mixed with blood ceased. Intramuscular injection for 5 days stopped the coughing completely. After 2 months of continued injection, the patient was cured.
(Experiment 3) As an Anti-Cancer Drug (Supplementary Treatment) 1) Injection produced in Case Study 2 A patient with stomach cancer (51 years old, female) in terminal stage was given intramuscular injection for 2 days (once a day, 2ιn£ per injection). As result, cancer cell de-activation effect manifested after 2 days (The patient, who previously could not swallow food, could now eat and urinate without assistance).
(Experiment 4) Nephritis Treatment Effect 1) Injection produced in Case Study 2
Chronic nephritis patient (36 years old, female, oliguria, proteinuria, the whole body edema) was given intramuscular injection for 2 days (once a day, 2ml, dose per injection). The whole body edema disappeared and proteinuria and oliguria disappeared after 5 days of continued intramuscular injection. After 30 days of intramuscular injections (once a day, 2\\ύ per injection), the patient was cured.
(Experiment 5) Liver Disease Treatment Effect 1) Injection produced in Case Study 2 A patient suffering from inflammation of the liver (46 years old, female; patient with AST : 385, ALT : 650) was given intramuscular injection (once a day, 2\\ dose per injection). After 5 days of intramuscular injections, the patient's AST and ALT was 88 and 92, respectively. After 15 days of intramuscular injections, the patient's AST and ALT decreased to 40 and 32, respectively, and the patient was cured.
(Experiment 6) As an Anti-Rheumatism, Anti- Arthritis Treatment 1) Injection produced in Case Study 2
A patient with Rheumatoid Arthritis (38 years old; less than 60o Of the knee joint's degree of movement was given one dose of intramuscular injection (2ι.ιβ. dose). Swelling of the knees disappeared on the same day. The patient's joints also became flexible and soft. After 30 days of continued intramuscular injections (once a day, 2ml dose per injection), the patient was cured.
(Experiment 7) As Treatment for Various Inflammatory Diseases 1) Injection produced in Case Study 2
A patient suffering from acute inflammation of the middle ear (10 years old, female) was given one-time intramuscular injection (lml dose). The pain associated with the inflammation disappeared and after 3 days of intramuscular injections (once a day, lml dose per injection), the acute inflammation of the middle ear was cured. 2) Injection produced in Case Study 2
A patient suffering from tonsilitis (12 years old, male; size of the inflamed area: 0.5cm in diameter) was given intramuscular injection for 3 days (once a day, lmC dose per injection) and the inflammation of the tonsils was cured. 3) Injection produced in Case Study 2 A patient suffering from the teethbridge disease (30 years old, male) in the gums of a canine tooth was given an intramuscular injection (2ml per injection). After a day , the patient was cured.

Claims

[Claims]
[Claim 1]
Therapeutic medicine (for injection application), characterized by the precipitated and purified materials produced by the mixture of main ingredients, resin or pine needle and Terpene protein and by mixing these main ingredients in the pot to heat and then cool off.
[Claim 2]
Regarding Claim 1, therapy for injection , characterized by the composition of as main ingredients (30-95% of weight) and the yellow and white parts of egg taking up 5-70% of weight.
[Claim 3]
Regarding Claim 1 or Claim 2, injection characterized by invention's anti-tuberculosis treatment effect
[Claim 4]
Regarding Claim 1 or Claim 2, injection characterized by invention's cancer cell de- activation effect (as supplementary treatment)
[Claim 5]
Regarding Claim 1 or Claim 2, injection characterized by invention's nephritis treatment effect
[Claim 6]
Regarding Claim 1 or Claim 2, injection characterized by invention's liver disease treatment effect
[Claim 7] Regarding Claim 1 or Claim 2, injection characterized by invention's rheumatism arthritis treatment effect
[Claim 8]
Regarding Claim 1 or Claim 2, injection characterized by the elimination of various inflammations
PCT/KR2001/000897 2000-05-29 2001-05-28 An-egg protein anti-cancer injection drug and a procedure to obtain such a drug WO2001091777A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001264339A AU2001264339A1 (en) 2000-05-29 2001-05-28 An-egg protein anti-cancer injection drug and a procedure to obtain such a drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020000029155A KR20010107474A (en) 2000-05-29 2000-05-29 Egg protein anti-cancer (egg protein anti-tuberculosis) combination treatment and preparation method thereof
KR2000/29155 2000-05-29

Publications (1)

Publication Number Publication Date
WO2001091777A1 true WO2001091777A1 (en) 2001-12-06

Family

ID=19670768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2001/000897 WO2001091777A1 (en) 2000-05-29 2001-05-28 An-egg protein anti-cancer injection drug and a procedure to obtain such a drug

Country Status (3)

Country Link
KR (1) KR20010107474A (en)
AU (1) AU2001264339A1 (en)
WO (1) WO2001091777A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010107474A (en) * 2000-05-29 2001-12-07 소무철 Egg protein anti-cancer (egg protein anti-tuberculosis) combination treatment and preparation method thereof
KR20030017792A (en) * 2001-08-22 2003-03-04 소무철 phytoncide omitted
EP1312370A1 (en) * 2001-11-16 2003-05-21 Iijima Corporation Composition comprising dried whole egg for treating hepatitis
WO2013053503A1 (en) 2011-10-13 2013-04-18 Cunill Aixela Juan Egg preparation with regenerating, analgesic and/or anti-inflammatory properties
EP3744338A1 (en) * 2019-05-30 2020-12-02 Ugur Yem Katki Maddeleri San. ve Tic. Ltd. Sti. Medical uses of red pine resin and dosage forms therof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207336A (en) * 1985-03-12 1986-09-13 Yasumasa Mimura Analgesic and anti-inflammatory agent
JPS62205032A (en) * 1986-03-04 1987-09-09 Hiroshi Sakagami Carcinostatic agent
EP0472003A1 (en) * 1990-08-20 1992-02-26 Nihon Nosan Kogyo K.K. Anti-inflammatory composite containing iodine enriched eggs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010107474A (en) * 2000-05-29 2001-12-07 소무철 Egg protein anti-cancer (egg protein anti-tuberculosis) combination treatment and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207336A (en) * 1985-03-12 1986-09-13 Yasumasa Mimura Analgesic and anti-inflammatory agent
JPS62205032A (en) * 1986-03-04 1987-09-09 Hiroshi Sakagami Carcinostatic agent
EP0472003A1 (en) * 1990-08-20 1992-02-26 Nihon Nosan Kogyo K.K. Anti-inflammatory composite containing iodine enriched eggs

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010107474A (en) * 2000-05-29 2001-12-07 소무철 Egg protein anti-cancer (egg protein anti-tuberculosis) combination treatment and preparation method thereof
KR20030017792A (en) * 2001-08-22 2003-03-04 소무철 phytoncide omitted
EP1312370A1 (en) * 2001-11-16 2003-05-21 Iijima Corporation Composition comprising dried whole egg for treating hepatitis
US6720010B2 (en) 2001-11-16 2004-04-13 Iijima Corporation Composition having antihepatitic activity
WO2013053503A1 (en) 2011-10-13 2013-04-18 Cunill Aixela Juan Egg preparation with regenerating, analgesic and/or anti-inflammatory properties
AU2012323427B2 (en) * 2011-10-13 2015-08-27 Ovivity Group S.L. Egg preparation with regenerating, analgesic and/or anti-inflammatory properties
US9717764B2 (en) 2011-10-13 2017-08-01 Ovivity Group, S.L. Egg preparation with regenerating, analgesic and/or anti-inflammatory properties
EP3744338A1 (en) * 2019-05-30 2020-12-02 Ugur Yem Katki Maddeleri San. ve Tic. Ltd. Sti. Medical uses of red pine resin and dosage forms therof

Also Published As

Publication number Publication date
AU2001264339A1 (en) 2001-12-11
KR20010107474A (en) 2001-12-07

Similar Documents

Publication Publication Date Title
JP2003521520A (en) Therapeutic agent containing as an active ingredient anemonin for non-bacterial inflammation
RU2419449C1 (en) Medication for treatment of patients with drug hepatitis
CN101167937A (en) Traditional Chinese medicinal composition plaster for curing rheumatism or rheumatoid diseases and preparation method thereof
WO2001091777A1 (en) An-egg protein anti-cancer injection drug and a procedure to obtain such a drug
CN101648000B (en) Application of cobrotoxin in preparing medicine for treating arthritis
CN101301460B (en) Rheumatism paste for resolving stasis
CN109303811A (en) The exterior-applied medical wine of activating microcirculation and removing stasis medicinal anti-inflammatory analgetic
CN101485754B (en) Medicament for treating gastropathy and preparation method
MXPA06003744A (en) Use of extracts from the pelargonium species.
CN113521221A (en) Sealwort ointment traditional Chinese medicine prescription with monarch, minister, assistant and guide compatibility
CN105687444A (en) Traditional Chinese medicine composition for treating rheumatism and preparation method and application thereof
CN110876796A (en) Traditional Chinese medicine composition for treating acute gout attack and preparation method and application thereof
CN1814077A (en) Medicinal liquor for treating hemorrhoids
CN1141117C (en) Aloe wine for treating injury
CN102626479B (en) External-use Chinese herbal medicine composition for chronic rheumatism treatment
CN104688936A (en) Traditional Chinese medicine composition for treating burns and scalds and preparation thereof
CN1212148C (en) External plaster of sea horse and soft-shelled turtle
Verma et al. MANAGEMENT OF AMAVATA WSR TO RHEUMATOID ARTHRITIS: A CASE STUDY
CN106563109B (en) Medicine for treating knee osteoarthritis and preparation method thereof
RU2122418C1 (en) Agent for treatment of patients with chronic hepatitis of an infectious etiology
CN114917309A (en) Dai medicine composition for external use for treating gouty arthritis and application
CN1143684C (en) Medicine for treating hypertension and heart disease and its preparation
CN115845003A (en) Application of traditional Chinese medicine composition in preparation of medicine for treating arthritis
TWI277420B (en) Medicine using anemonin as active pharmaceutical ingredient for treating aseptic inflammation
CN116983348A (en) Traditional Chinese medicine composition for inhibiting bone cancer pain and preparation and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP